F or 3 decades, vancomycin has been a favored therapy for serious penicillin-and cephalosporin-resistant Gram-positive bacterial infections. Development of vancomycin resistance may have been restrained by the requirement for intravenous administration, which limited its use and lessened exposure to the gastrointestinal flora. Nevertheless, physicians are increasingly encountering children and adults infected with vancomycin-resistant Gram-positive organisms. Resistance to vancomycin has been encountered in all commonly occurring, clinically significant Gram-positive bacterial species except Streptococcus pyogenes, Streptococcus pneumoniae, and Streptococcus agalactiae. 1 Although therapeutic options are usually guided by the antimicrobial susceptibilities of individual isolates, recommended infection-control measures vary with the specific species and the mechanism of resistance.
VANCOMYCIN-RESISTANT STAPHYLOCOCCUS AUREUS
Vancomycin-resistant Staphylococcus aureus (VRSA) were first recognized in Japan in 1996; the first case of infection due to VRSA in the United States was reported in 2002. 2 Since then, at least 8 additional cases of VRSA infection have been identified in the United States, with more than half of these cases occurring in Michigan. 3, 4 Isolates often seem to have evolved independently in settings where patients were previously colonized with vancomycin-resistant enterococcus (VRE) and methicillin-resistant S. aureus (MRSA). 4 Environments that promote biofilm formation may facilitate transmission of resistance from VRE to MRSA. 4 VRSA isolates (vancomycin MIC Ն16 g/mL) are fundamentally different from vancomycin-intermediate S. aureus (VISA) isolates (vancomycin MIC ϭ 4 -8 g/mL).
2 Resistance in VISA isolates is typically mediated via mechanisms that develop in the presence of vancomycin and are not readily transferrable to other strains. The potential for spread of these isolates is low in the absence of vancomycin therapy. In contrast, VRSA isolates uniformly contain the vanA gene derived from enterococcus (discussed below). The VanA phenotype is transferable to other MRSA strains and across microbial species, with a much greater potential for spread, even in the absence of vancomycin therapy. 2 Thus far, VRSA outbreaks have not occurred; however, because of the potential for spread with dire consequences, a case of VRSA infection warrants a more rigorous infection-control response than a case of infection with MRSA, VISA, or VRE. Infection-control measures should be implemented urgently according to a written plan, if VRSA is suspected. 2 The local health department and the Centers for Disease Control and Prevention should be consulted immediately. Management of contacts should occur according to contact categorization. Attempts to decolonize individuals who are found to be colonized should be considered on a case-by-case basis.
Infections with S. aureus isolates that have vancomycin MICs Ն4 g/mL typically do not respond clinically to vancomycin therapy. 2 To date, all VRSA have also been found to be resistant to methicillin. Fortunately, all VRSA and VISA isolates have been susceptible to one or more commercially available antibiotics. Recommended antibiotics for VRSA and VISA, according to susceptibilities and other clinical considerations, are listed in Table 1. 2,4 Secondary agents include teicoplanin (not available in the United States), trimethoprim-sulfamethoxazole, tetracycline, rifampin (usually in combination therapy), and chloramphenicol.
VANCOMYCIN-RESISTANT ENTEROCOCCI
VRE infection was first reported in 1988. 5 Subsequently, infections with VRE in the United States have been observed primarily in large teaching hospitals. 6, 7 Not only are VRE found in all regions of the United States, 8 but the rate of vancomycin resistance among enterococci isolated from patients in this country is higher than the rates in Canada, Western Europe, and Latin America, 8 possibly related to the widespread use of vancomycin in the United States. 9 Perhaps, as a consequence of relatively better overall health status in hospitalized children compared to hospitalized adults, VRE infections in children have occurred less frequently than in adults, and overall rates of vancomycin resistance in enterococci isolated from children's hospitals remain relatively low. 10 Vancomycin resistance among enterococci is phenotypically and genotypically heterogeneous, and may not predict resistance to other glycopeptides, including teicoplanin and televancin. 11, 12 Vancomycin inhibits the synthesis of peptidoglycan, disrupting the cell wall of Gram-positive bacteria. Vancomycin resistance is due to the presence of the van gene encoding substratespecific enzymes responsible for either the synthesis of low affinity precursors (modifying the vancomycin binding target) or for elimination of high affinity precursors (removing the vancomycin binding target). 12 Six major phenotypes of vancomycin resistance (VanA, VanB, VanC, VanD, VanE, and VanG) have been characterized (Table 2) . 1, 12 VanA and VanB phenotypes are both common and transferable. The VanA phenotype confers highlevel resistance to vancomycin and teicoplanin, whereas the VanB phenotype exhibits variable levels of resistance to vancomycin, but not teicoplanin.
11,12 The VanC phenotype is not transferable and is limited to Enterococcus gallinarum and Enterococcus casseliflavus (Enterococcus flavescens).
11 VanD, VanE, and VanG phenotypes are uncommon ( Table 2) .
The emergence of VRE has complicated the treatment guidelines for enterococcal endocarditis and other serious enterococcal infections, such that the optimal therapy for infections caused by VRE remains uncertain. Enterococci resistant to vancomycin (VanB, but not VanA phenotype) may remain susceptible to teicoplanin or the just approved telavancin. However, teicoplanin is not available in the United States and treatment of endocarditis with this agent has been associated with both treatment failure and relapse. 13 VRE infections susceptible to beta-lactams may be treated with ampicillin plus an aminoglycoside. Unfortunately, the VanA phenotype is frequently associated with strains of Enterococcus faecium, which are increasingly resistant to beta-lactams. If high-level resistance to aminoglycosides is not present, triple-combination therapy with a beta-lactam, a glycopeptide, and an aminoglycoside may achieve bactericidal activity, as shown in animal models.
14 Although several agents (quinupristin-dalfopristin, linezolid, and daptomycin) are available for the treatment of VRE infections in adults (Table 1) , only linezolid has been approved for use in children. Resistance of enterococcal isolates 
PREVENTION
Curtailing agricultural use of antibiotics and judicial use of antimicrobials in dayto-day clinical practice are ultimately the best hope to curb the emergence of vancomycin-resistant bacteria. Prompt recognition and isolation of potentially pivotal breakthrough cases of vancomycin-resistant bacteria could prevent global outbreaks of newly resistant strains.
